PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVonoprazan
Vonoprazan
Voquezna (vonoprazan) is a small molecule pharmaceutical. Vonoprazan was first approved as Voquezna triple pak on 2022-05-03. It is used to treat helicobacter pylori in the USA.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Voquezna
Combinations
Voquezna dual, Voquezna triple
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
+
Vonoprazan fumarate
Tradename
Company
Number
Date
Products
VOQUEZNA DUAL PAKPhathom PharmaceuticalsN-215153 RX2022-05-03
1 products, RLD, RS
Amoxicillin
+
Clarithromycin
+
Vonoprazan fumarate
Tradename
Company
Number
Date
Products
VOQUEZNA TRIPLE PAKPhathom PharmaceuticalsN-215152 RX2022-05-03
1 products, RLD, RS
Vonoprazan fumarate
Tradename
Company
Number
Date
Products
VOQUEZNAPhathom PharmaceuticalsN-215151 RX2023-11-01
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
voqueznaNew Drug Application2024-07-22
voquezna dual pak voquezna triple pakNew Drug Application2025-07-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urinary tract infectionsEFO_0003103D014552N39.0
sinusitisEFO_0007486D012852J32
otitis mediaEFO_0004992D010033H66.9
bacterial infections—D001424A49
bacterial skin diseases—D017192—
soft tissue infections—D018461—
chlamydia infectionsEFO_0007205D002690A74.9
helicobacter infectionsEFO_1000961D016481—
duodenal ulcerEFO_0004607D004381K26
streptococcal infectionsEFO_1001476D013290—
Show 12 more
Agency Specific
FDA
EMA
Expiration
Code
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM
2032-05-03GAIN
2027-05-03NCE
AMOXICILLIN / VONOPRAZAN FUMARATE, VOQUEZNA DUAL PAK, PHATHOM
2032-05-03GAIN
2027-05-03NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Amoxicillin / Clarithromycin / Vonoprazan Fumarate, Voquezna Triple Pak, Phathom
91864112030-08-11DP
79774882028-08-11DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC08: Vonoprazan
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD14: Vonoprazan, amoxicillin and clarithromycin
— A02BD15: Vonoprazan, amoxicillin and metronidazole
HCPCS
No data
Clinical
Clinical Trials
146 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—425262056
Helicobacter infectionsD016481EFO_1000961—23481531
Gastroesophageal refluxD005764EFO_0003948K215234620
EsophagitisD004941HP_0100633K202—73618
UlcerD014456MPATH_579—11111317
GastritisD005756EFO_0000217K29.72—38215
Stomach ulcerD013276—K251—81212
Peptic esophagitisD004942EFO_1001095—2—23411
Communicable diseasesD003141————14510
Peptic ulcerD010437—K2711—3—5
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Duodenal ulcerD004381EFO_0004607K26——8—412
Healthy volunteers/patients———9—1——10
HeartburnD006356—R12111—14
HypertensionD006973EFO_0000537I10——1——1
Portal hypertensionD006975EFO_0000666K76.6——1——1
Treatment outcomeD016896————1——1
Adolescent developmentD041923————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Eosinophilic esophagitisD057765EFO_0004232K20.0—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——————22
B-cell lymphoma marginal zoneD018442—C88.4————11
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3————11
Thrombocytopenic purpuraD011696——————11
PurpuraD011693HP_0000979D69.2————11
Patient participationD010358——————11
Gastrointestinal microbiomeD000069196——————11
Disease susceptibilityD004198——————11
TherapeuticsD013812——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVonoprazan
INNvonoprazan
Description
Vonoprazan is a member of pyrroles.
Classification
Small molecule
Drug classproton pump inhibitors, not dependent on acid activation
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1
Identifiers
PDB—
CAS-ID881681-00-1
RxCUI—
ChEMBL IDCHEMBL2079130
ChEBI ID—
PubChem CID15981397
DrugBankDB11739
UNII ID1R5L3J156G (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Voquezna – Phathom Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,639 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,001 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use